These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29616482)

  • 1. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
    Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
    Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative biochemical efficacy analysis of an alpha
    Li Z; Franke RM; Morris D; Yel L
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
    Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.
    Barros-Tizón JC; Torres ML; Blanco I; Martínez MT;
    Ther Adv Respir Dis; 2012 Apr; 6(2):67-78. PubMed ID: 22354900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.
    Greulich T
    COPD; 2017 Mar; 14(sup1):S8-S11. PubMed ID: 28306355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
    Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
    Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).
    Sandhaus RA; Stocks J; Rouhani FN; Brantly M; Strauss P
    COPD; 2014 Feb; 11(1):17-25. PubMed ID: 23822603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
    Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
    Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
    Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
    Campos MA; Lascano J
    Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.
    Ma S; Lin YY; He J; Rouhani FN; Brantly M; Turino GM
    COPD; 2013 Aug; 10(4):473-81. PubMed ID: 23560990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The direct medical costs of alpha(1)-antitrypsin deficiency.
    Mullins CD; Huang X; Merchant S; Stoller JK;
    Chest; 2001 Mar; 119(3):745-52. PubMed ID: 11243952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
    Louie SG; Sclar DA; Gill MA
    Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
    Lieberman J
    Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.
    Campos MA; Alazemi S; Zhang G; Wanner A; Salathe M; Baier H; Sandhaus RA
    Respir Med; 2009 Oct; 103(10):1532-9. PubMed ID: 19464158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD.
    Stolk J; Tov N; Chapman KR; Fernandez P; MacNee W; Hopkinson NS; Piitulainen E; Seersholm N; Vogelmeier CF; Bals R; McElvaney G; Stockley RA
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31467115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.